1/6

ADVANCED

IMMUNOTHERAPEUTICS

FOR ANIMAL HEALTH

MBFT Email Currently Down

Starting Wednesday September 25th our email service has been down.  We expect our email service to be back by 3pm EST September 27th.  Sorry for any inconvenience this might have caused.

Turbo-Charged Vaccines for Animal Health™

 

Man’s Best Friends Therapeutics (MBFT) is a clinical stage animal health company that is developing innovative gene-based check point inhibitor and immune-modulators for cancer and infectious diseases for use in veterinary medicine, using both viral and non-viral proprietary delivery systems. This is a technology platform from which multiple prophylactic and therapeutic vaccines can be developed for markets valued at over $5BM in the USA. Our lead product is MBFT-201 for canine melanoma. We have completed 2 pilot studies that have demonstrated the safety of our immunotherapeutic vaccine and have elicited a strong cytotoxic T-cell responses to the key antigens in 100% of the dogs treated.

 

In addition we have 3 infectious disease products in development. Our infectious disease products will utilize our proprietary non-viral delivery system that elicits both a T and B-cell response, is dose sparing, allows for re-administration and can be customized to optimize the immune response for each vaccine.

The Lastest in the News:

  • LinkedIn Classic
  • Facebook Classic
  • Twitter Social Icon

​Follow us at @mbftherapeutics

© 2013 MBF Therapeutics